TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19943881
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg day(-1)
Study: 19943881
Drug: Enoxaparin 1
Normalized name: ENOXAPARIN 100MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1 mg kg(-1) twice daily
Study: 12642046
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg on the first day, followed by 250 mg daily for 4 days)
Study: 1951212
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (IVIG) 750 mg/kg administered within 72 hours of admission and every 14 days until discharge or age 3 months.
Study: 1951212
Drug: Placebo (albumin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (albumin) administered within 72 hours of admission and every 14 days until discharge or age 3 months.
Study: 8033435
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (IVIG)
Study: 20195589
Drug: Salbutamol via
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol via pressurized metered-dose inhaler with spacer (50 microg/kg)
Study: 18640172
Drug: Conventional cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cigarette (CC)
Study: 1900011
Drug: rt-PA with
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rt-PA with intravenous metoprolol 15 mg acutely and then 200 mg orally daily
Study: 6141051
Drug: Felodipine (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (6.25 mg to 25 mg)
Study: 30191722
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioural therapy for insomnia (Sleep Healthy Using The Internet)
Study: 25652579
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioural therapy for insomnia
Study: 30236079
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment plus I3C and EGCG plus long-term platinum-taxane chemotherapy (arm 3)
Study: 30236079
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment alone without neoadjuvant platinum-taxane chemotherapy (control arm 4)
Study: 30236079
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment alone (control arm 5)
Study: 1587073
Drug: Augmented therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented therapy
Study: 10206320
Drug: Azimilide 100
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide 100 mg day(-1)
Study: 10206320
Drug: Azimilide 150
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide 150 mg day(-1)
Study: 10206320
Drug: Azimilide 200
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide 200 mg day(-1)
Study: 10206320
Drug: Azimilide 100
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide 100 mg day(-1) with 3-day loading for >55 years
Study: 30430
Drug: Methylphenidate, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate, 0.5 mg/kg intravenously
Study: 31081694
Drug: Tirasemtiv (tolerated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirasemtiv (tolerated dose)
Study: 26944609
Drug: Cortisol administration
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol administration
Study: 20008240
Drug: Maintenance or
Normalized name: Cystex Urinary Health Maintenance oral soluti
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance or consolidation therapies
Study: 20008240
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with novel agents
Study: 17442550
Drug: NSAIDs (aspirin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (aspirin, ibuprofen)
Study: 23937999
Drug: Paracetamol (acetaminophen)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (acetaminophen)
Study: 11772663
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) steroid plus oral placebo
Study: 11772663
Drug: Oral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroid plus IM placebo
Study: 9833199
Drug: Outpatient therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient therapy, drop-in center, and brokered case management
Study: 2286465
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg)
Study: 10884878
Drug: Cefotaxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1 g)
Study: 2504593
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ofloxacin and cefotaxime
Study: 341901
Drug: fluocortin butylester
Normalized name: fluocortin
DrugBank: Fluocortin (DB13223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluocortin butylester (Vaspit) in cream, ointment, and fatty ointment
Study: 28407129
Drug: Citrate-containing dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate-containing dialysate plus a heparin-grafted membrane (CiTED)
Study: 25997827
Drug: 150 mL
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mL ropivacaine (2 mg/mL) and 0.5 mL epinephrine (1 mg/mL)
Study: 25997827
Drug: 150 mL
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mL 0.9% saline (control)
Study: 23652169
Drug: Intraoperative colloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative colloid administration
Study: 23652169
Drug: No intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intraoperative colloid administration
Study: 17111006
Drug: CHO +
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO + EAA + Glutamine (0.3 g/kg BW)
Study: 8773436
Drug: Aminophylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (5 mg/kg over 20 min)
Study: 28743247
Drug: Paclitaxel monotherapy
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel monotherapy (80 mg/m2 weekly, 3 weeks on, 1 week off)
Study: 28743247
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus sorafenib (400 mg orally, twice a day, starting dose of 200 mg)
Study: 22298569
Drug: WR(+) -
Approvals — FDA: no, EMA: no, PMDA: no
Description: WR(+) - wheat/rye bread with in situ‐produced AXOS (180 g/d)
Study: 22298569
Drug: W(‐) -
Approvals — FDA: no, EMA: no, PMDA: no
Description: W(‐) - refined wheat flour bread without AXOS (180 g/d)
Study: 20570218
Drug: Brachytherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brachytherapy with (125)I seed implants, prescription dose of 145 Gy.
Study: 20570218
Drug: Brachytherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brachytherapy with (125)I seed implants in non-small prostate volume patients, 120 patients in total.
Study: 26925905
Drug: Liposic ointment
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposic ointment
Study: 21223250
Drug: Reduced chemotherapy
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced chemotherapy (standard risk; SR)
Study: 21223250
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (medium risk; MR)
Study: 19895208
Drug: Standard short-course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard short-course anti-TB treatment (2EHRZ3/4RH3)
Study: 16052108
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 microg/kg over 15 min followed by 0.2 microg x kg x h infusion)
Study: 16052108
Drug: Fentanyl (0.1-0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.1-0.2 mg intravenous on demand)
Study: 9845131
Drug: 5-Fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-Fluorouracil (5FU) and cisplatin (CDDP) chemotherapy
Study: 30348127
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no chemotherapy)
Study: 8082346
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg bolus injection of alteplase over 15 min (maximum dose 50 mg)
Study: 30520111
Drug: 308-nm excimer
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 308-nm excimer laser monotherapy
Study: 19793378
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg/day (alpha‐blocker group)
Study: 19793378
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tamsulosin 0.2 mg/day and dutasteride 0.5 mg/day
Study: 17693178
Drug: Aspirin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75 mg per day)
Study: 9797360
Drug: Ciprofloxacin (500-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500-750 mg twice a day)
Study: 8106700
Drug: Metoprolol (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (titrated to a mean maximal dose of 87 mg/day)
Study: 2764852
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg, t.i.d.)
Study: 21726916
Drug: glimepiride-metformin
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: glimepiride-metformin
Study: 17126774
Drug: Propofol (Diprifusor)
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol (Diprifusor) target-controlled infusion at a predetermined target concentration starting at 2.5 mug/mL; step size of 0.1 microg/mL
Study: 17126774
Drug: Propofol (Diprifusor)
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol (Diprifusor) target-controlled infusion
Study: 14559317
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil omega-3 fatty acids (4.5 g/d) + sulfasalazine (2 g/d)
Study: 14559317
Drug: Sulfasalazine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (2 g/d) alone
Study: 16918888
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg/day)
Study: 6374866
Drug: Oxmetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxmetidine 400 mg twice daily
Study: 482183
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g daily
Study: 23314489
Drug: 12 daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 daily local mud packs and generalized thermal baths with sulfate‐calcium‐magnesium‐fluorides mineral water added to usual treatment
Study: 23314489
Drug: Regular outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular outpatient care routine (exercise, NSAIDs and/or analgesics)
Study: 23314489
Drug: 12 daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 daily local mud packs and generalized thermal baths
Study: 22170369
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g WG/d for 16 wk
Study: 22170369
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g WG/d for 8 wk followed by 120 g WG/d for 8 wk
Study: 15786932
Drug: PADMA 28,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PADMA 28, 3 x 2 capsules daily for 4 weeks
Study: 8543487
Drug: Meropenem 500
Normalized name: meropenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 500 mg bd
Study: 8543487
Drug: Imipenem/cilastatin 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin 500 mg bd
Study: 8543487
Drug: Meropenem 500
Normalized name: meropenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 500 mg tds
Study: 8543487
Drug: Ceftazidime 500
Normalized name: ceftazidime 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 500 mg tds
Study: 8288503
Drug: Ceftazidime 1
Normalized name: ceftazidime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 1 g tds
Study: 1962599
Drug: Droloxifene 20
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 20 mg once daily
Study: 1962599
Drug: Droloxifene 40
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 40 mg once daily
Study: 7046782
Drug: Ordinary terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary terbutaline 5 mg three times daily
Study: 19680279
Drug: Other treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatment options (control group)
Study: 18004683
Drug: 0.3 g.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g.kg(‐1) BW NaHCO3 ingestion with passive recovery (BICARB P)
Study: 18004683
Drug: 0.3 g.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g.kg(‐1) BW NaHCO3 ingestion with active recovery (BICARB A)
Study: 16421365
Drug: Inhaled hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled hypertonic saline (5 ml of 7 percent sodium chloride) four times daily without amiloride pretreatment
Study: 16421365
Drug: Inhaled hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled hypertonic saline with amiloride pretreatment
Study: 8873228
Drug: Nabumetone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone (1000 mg once daily)
Study: 15556830
Drug: Rofecoxib (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (12.5 mg)
Study: 3877303
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg bolus injection over 5 seconds
Study: 3877303
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg bolus injection
Study: 3877303
Drug: Propofol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.5 mg/kg and 2.0 mg/kg
Study: 30102965
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of toreforant once daily through week 24
Study: 24901463
Drug: Announced pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Announced pill count
Study: 12759558
Drug: Fluoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine treatment for 8 weeks (control group)
Study: 10698385
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide 40 ppm
Study: 2870222
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 mg three times a day)
Study: 2870222
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 mg twice a day)
Study: 27141627
Drug: Scalp acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp acupuncture treatment
Study: 24140220
Drug: Prophylactic intravenous
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intravenous antibiotics
Study: 17490928
Drug: Glipizide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide (10 mg daily for 12 weeks)
Study: 11833827
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 to 300 mg/d
Study: 11833827
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 to 20 mg/d
Study: 8625624
Drug: 10% low‐molecular‐weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% low‐molecular‐weight hydroxyethyl starch solution
Study: 21892106
Drug: Arm A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: 40 Gy/20 fractions/4 weeks with concurrent weekly vinorelbine 25 mg/m + cisplatin 20 mg/m
Study: 21892106
Drug: Arm B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: 30 Gy/15 fractions/3 weeks with concurrent weekly gemcitabine 200 mg
Study: 10689005
Drug: Crinone 8%
Normalized name: Crinone 8% Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone 8% (90 mg vaginally)
Study: 10689005
Drug: Prometrium (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prometrium (100 mg orally)
Study: 27229736
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (n=26): twice weekly 60-min group exercise classes, at least 3 days/week self-directed exercise, daily pedometer, weekly telephone counseling
Study: 23901023
Drug: EGCG-rich green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: EGCG-rich green tea extract (300-900 mg/day)
Study: 18303408
Drug: Neoadjuvant platinum/taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant platinum/taxanes chemotherapy
Study: 9174478
Drug: Reduced calcium
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced calcium intake (280 mg/d)
Study: 31427252
Drug: Amoxicillin-clavulanate (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (45 mg/kg per day)
Study: 31427252
Drug: Azithromycin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (5 mg/kg per day)
Study: 25024070
Drug: T-DM1 3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-DM1 3.6 mg/kg every 3 weeks
Study: 22967970
Drug: salvia miltiorrhiza
Normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: salvia miltiorrhiza and ligustrazine injection (250 mL glucose injection containing 10 mL concoction, once a day for three days)
Study: 22967970
Drug: routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: routine treatment methods (fluid resuscitation, anti‐infection treatment, support treatment, organ‐protection treatment)
Study: 21385192
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg b.d. for 12 months
Study: 21385192
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg b.d. for 12 months
Study: 2062329
Drug: 600 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 micrograms of inhaled budesonide twice a day
Study: 29964041
Drug: Prebiotic supplement
Normalized name: FlorastorSelect Gut Boost Daily Probiotic and Prebiotic Supplement Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic supplement (2.8 g/d Bimuno containing 1.37 g beta-galactooligosaccharide) plus placebo (Mediterranean-type diet)
Study: 29964041
Drug: Placebo supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplement (2.8 g xylose) plus low-FODMAP diet
Study: 24918721
Drug: Topical policresulen
Normalized name: policresulen
DrugBank: Policresulen (DB13492)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical policresulen + cinchocaine
Study: 24918721
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual guidelines with oral medications)
Study: 12209517
Drug: Low-dose IV
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IV CYC (500 mg, 6 fortnightly pulses) followed by AZA
Study: 12209517
Drug: High-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IV CYC (6 monthly pulses and 2 quarterly pulses, doses increased according to WBC count) followed by AZA
Study: 25063793
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg once daily)
Study: 25063793
Drug: GTN (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN (0.6 mg/h, 2 h/day)
Study: 2053453
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg of elemental calcium supplementation
Study: 12010667
Drug: High-dose UFH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose UFH (12,500 IU for one week followed by 10,000 IU)
Study: 7644088
Drug: Ketanserin 20-40
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 20-40 mg bid for three weeks
Study: 7644088
Drug: Enalapril 10-20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10-20 mg bid for three weeks
Study: 23500313
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose of diuretics
Study: 12632341
Drug: High-dose cisplatin-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin-based chemotherapy (HDPEB)
Study: 18555147
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (both groups)
Study: 31869430
Drug: Glyburide/Metformin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide/Metformin combination therapy (COMBO)
Study: 31869430
Drug: Metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET) and Glyburide/Metformin combination therapy (COMBO)
Study: 27733219
Drug: Ultrasound-guided TAP
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided TAP block with 0.5% ropivacaine 20 ml at 30 minutes before surgery
Study: 10957661
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin injections (HEP group)
Study: 10957661
Drug: Thigh-length sequential
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thigh-length sequential EPC device (EPC group)
Study: 10957661
Drug: Both subcutaneous
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both subcutaneous heparin injections and EPC device (HEP + EPC group)
Study: 9285071
Drug: B13/L2 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: B13/L2 supplementation (13 mg beta-carotene, 2 mg lycopene, 5 mg vitamin E, 30 mg vitamin C)